Trials / Terminated
TerminatedNCT05315817
Safety and Performance Evaluation of multiPlus Dialysate During CRRT
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Fresenius Medical Care Deutschland GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of the performance of multiPlus dialysate based on the serum creatinine removal 6 hours (360 min) after start of continuous veno-venous haemodialysis/ haemodiafiltration \[CVVHD(F)\]. multiPlus is a phosphate-containing dialysis solution for the use in continuous renal replacement therapy (CRRT) during acute kidney injury (AKI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | multiPlus dialysate | Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate. |
Timeline
- Start date
- 2022-05-31
- Primary completion
- 2022-10-28
- Completion
- 2023-01-24
- First posted
- 2022-04-07
- Last updated
- 2024-01-09
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05315817. Inclusion in this directory is not an endorsement.